Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
21 sept. 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
21 sept. 2021 05h53 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
08 sept. 2021 10h02 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Intrommune Therapeutics Launches #PeanutAllergyStrong
24 août 2021 12h25 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
11 août 2021 13h37 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies
09 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies ...
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
28 juil. 2021 14h10 HE
|
Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
22 juil. 2021 16h57 HE
|
Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics to Present at BIO Digital 2021
17 juin 2021 09h11 HE
|
Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Names Chief Operating Officer
25 mars 2021 09h10 HE
|
Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...